About the Project
As part of the 2016 Capital Plan for the Framingham campus, the approximately $11M renovation of the Genzyme Manufacturing Science and Technology (MSAT) laboratory on the recently vacated 2nd floor at 45 New York Avenue was undertaken. The new consolidated lab increased the capacity of the site MSAT organization to execute key Site and Corporate Objectives and support implementation of a new generation processes requiring in-depth analyses beyond the scope of the existing site capabilities.
Managed by Genzyme Capital Projects, Hereva provided cost controls and financial reporting for the duration of the project. This required monthly reconciliation of all purchase orders and invoices against Genzyme Project Tracking and SAP system reports with input of data into a complex, detailed report which separates the project into 28 individual cost categories, each with several sub categories. This report informed Sanofi Genzyme finance and senior executives on overall project costs monthly, provided a glimpse into anticipated cost overages/savings and was aimed at assisting with benchmarking similar projects in the future.
About the Client
Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofi’s programs in oncology and immunology.
Our approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, we rapidly grew to become one of the world’s leading biotechnology companies, recognized for our pioneering development of treatments for rare genetic disorders and our innovative contributions to medical science and biomanufacturing.